Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Anna Wiygul

Nurse Practitioner, Family Oxford, MS Nurse Practitioner

NPI 1619496403 CMS profile 11077798

504 Azalea Dr Ste A, Oxford, MS 38655

Open in the dashboard

General payments

$14,582

777 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anna Wiygul of Oxford, MS is reported in the CMS Open Payments database as having received $14,582 across 777 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,177 158
2024 General $3,467 186
2023 General $3,145 172
2022 General $2,720 160
2021 General $2,074 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anna Wiygul
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Anna Wiygul were reported at $3,177. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Anna Wiygul Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,074 $124 $35–$379 $132
2022 $2,720 $141 $44–$430 $149
2023 $3,145 $154 $49–$476 $160
2024 $3,467 $165 $51–$504 $164
2025 $3,177 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $1,385 82 payments
  2. Merck Sharp & Dohme Corporation $999 47 payments
  3. Janssen Biotech, Inc. $848 52 payments
  4. E.R. Squibb & Sons, L.L.C. $775 51 payments
  5. Pfizer Inc. $639 41 payments
  6. Lilly USA, LLC $589 32 payments
  7. Celgene Corporation $551 29 payments
  8. Gilead Sciences, Inc. $533 27 payments
  9. AstraZeneca Pharmaceuticals LP $512 28 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $490 21 payments
  11. Other $7,261 367 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,207 772 payments
  2. Education $375 5 payments
Products named General payments · program years 2021–2025
  1. KEYTRUDA $982 46 payments
  2. KISQALI $476 26 payments
  3. JAYPIRCA $451 23 payments
  4. XTANDI $428 23 payments
  5. IMBRUVICA $423 23 payments
  6. Lenvima $387 23 payments
  7. OPDIVO $383 26 payments
  8. XPOVIO $379 6 payments
  9. REBLOZYL $379 18 payments
  10. VERZENIO $373 21 payments
  11. Other $13,033 737 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

364

Median for Nurse Practitioner: 389

Drug cost

$43,385

Median for Nurse Practitioner: $21,885

Branded share of claims

33%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 22 $18,746
Xarelto Rivaroxaban Brand 26 $17,608
Exemestane Generic 21 $3,896
Letrozole Generic 46 $596
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 31 $540
Tamoxifen Citrate Generic 30 $468
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 27 $365
Potassium Chloride Generic 37 $217
Ondansetron Odt Ondansetron Brand 14 $198
Triamcinolone Acetonide Generic 12 $186

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$31,986

Medicare's payments for the services billed

Medicare patients

326

Average age 74

Services billed

717

180 women, 146 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 56%
Arthritis 54%
Diabetes 37%
Ischemic heart disease 37%
Chronic kidney disease 33%
Heart failure 26%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 75 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEYTRUDA
$181 — —
JAYPIRCA
$152 — —
KISQALI
$145 — —
NINLARO
$119 — —
ERLEADA
$115 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 75 with Patron

Records

777 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record